BN vs IBKR

The deterministic health scores present a mixed picture: the Piotroski F-Score of 4/9 indicates borderline stable financial health, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite a high forward P/E of 8.04 suggesting reasonable future earnings expectations, the trailing P/E of 131.03 reflects significant volatility or one-time impacts. Earnings growth is highly volatile with a YoY surge of 719.20%, but recent quarters show deteriorating performance, including a -91.3% YoY EPS drop and consistent earnings misses. The stock trades well above the Graham Number of $12.39 and intrinsic value of $10.62, implying substantial premium pricing based on growth and market sentiment rather than defensive or fundamental value.

IBKR exhibits stable financial health with a Piotroski F-Score of 6/9, though it currently trades at a significant premium to its Graham Number ($24.52) and slightly above its growth-based intrinsic value ($65.49). The company demonstrates exceptional operational efficiency with an operating margin of 78.8% and consistent earnings growth of 30.3% YoY. However, this fundamental strength is offset by bearish technical trends (10/100) and negative insider sentiment, with over $30M in recent sales. The stock is a high-quality compounder currently facing valuation headwinds.